All regulations
Nonrulemaking
FDA
Open for Comments
FDA-2026-P-5995
Requests that FDA declare that Ezetimibe and Simvastatin Tablets, 10 mg/15 mg & 10 mg/30 mg, are suitable for submission as ANDA. Petition used Organon LLC’s VYTORIN (ezetimibe and simvastatin) Tablets, approved for prescription under (NDA) 021687 in 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, & 10 mg/80 mg strengths. Petitioner seeks new strengths 10 mg/15 mg and 10 mg/30 mg for prescription use.
Documents
7
Comments
0
Description
OPEN
Key Dates
Comment Period OpensMay 28, 2026
Comment Period ClosesNov 25, 2026
Documents
| Type | Title | Status |
|---|---|---|
Supporting Material |
Keywords
CDER
Suitability Petition
Hyman, Phelps & McNamara PC
the Reference Listed Drug (“RLD”)
Organon LLC’s VYTORIN
(ezetimibe and simvastatin)
Tablets
is suitable for submission as an ANDA
Data from Regulations.gov